In the clinical trial set to begin later this year, about 3,800 men will receive a regimen of shots to test its efficacy.
If the vaccine is successful, it would be the first immunization against the deadly disease.
J&J is working to make a vaccine that will work in populations around the world that are infected with various strains of the virus. Other vaccines in late-stage studies have focused on preventing a single strain.
“The cost of treating HIV patients — the burden for patients, the burden for society — is very high,” Paul Stoffels, J&J’s chief scientific officer, told Bloomberg. HIV prevention is “a big mission for us. We’ve been working on it for almost 30 years.”
More articles on pharmacy:
Judge blocks HHS rule requiring drug prices in TV ads
Nation’s 1st prescription drug affordability board goes into effect
11 healthcare pharma leaders offer advice on controlling drug spend
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
